{"disease":{"id":"pseudomonas-aeruginosa-pneumonia","name":"pseudomonas aeruginosa pneumonia"},"drugs":{"marketed":[{"drug_id":"fusidic-acid","indication_name":"Synergy for Pseudomonas Aeruginosa Pneumonia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Synergy for Pseudomonas Aeruginosa Pneumonia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Pseudomonas Aeruginosa Pneumonia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03027609","title":"Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Aridis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01745796","title":"Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)","phase":"","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}